The cellular mechanism of action of terikalant, an investigational antiarrhythmic agent known
to block the inward rectifier and other potassium currents, has not yet been fully clarified. The …

The putative Class III antiarrhythmic benzopyran compound terikalant (RP62719) has been
applied to isolated rat ventricular myocytes. The drug, at extracellular concentrations from 1 …

We investigated the effects of terikalant, which blocks inward rectifier K+ current, on the
sinus rate, atrial and ventricular contractile force in the isolated, blood‐perfused right atrial …

The aim of the present study was to examine concentration-dependent effects of terikalant, a
blocker of inwardly rectifying K+ currents (IK1), rapidly activated delayed rectifying currents …

Ritanserin has been reported to be a potential antiarrhythmic. We studied the cellular
electrophysiologic effects of ritanserin in canine Purkinje fibers. Ritanserin produced …

Electrophysiological effects of bisaramil, a novel antiarrhythmic agent, were examined using
the conventional microelectrode technique applied to cardiac multicellular preparations from …

The action of tedisamil, a new bradycardiac agent with antiarrhythmic properties, was
investigated in single rat ventricular myocytes using the whole cell voltage-clamp technique …

Objectives The effects of almokalant (4-[3-ethyl [3-(propylsulphinyl) propyl]-amino]-2-hydroxy-
propoxyj-benzonitrile), E-4031 (1-[2-(6-methyl-2-pyridyl)-ethyl]-4-(4-methylsulphonyl-amino …

The electrophysiologic effects of ambasilide, a new class III antiarrhythmic drug reported to
be a nonselective blocker of both components (I Kr and I Ks) of the delayed-rectifier …

Rats were used to evaluate the antiarrhythmic properties of tedisamil, a novel agent with the
electrophysiological properties of a Class III antiarrhythmic drug. Tedisamil was tested …